Physician profile
Wayne J Fraser
NPI 1447352588
$4,726.11
in general payments reported to CMS, 2019-2025
28 companies · $35.67 in 2025
The $35.67 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,002 · 2020: $487 · 2021: $1,398 · 2022: $860 · 2023: $733 · 2024: $211 · 2025: $35.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $979.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,150.66 | 2019-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $787.01 | 2019-2024 | Breztri, Farxiga |
| Sanofi-Aventis U.S. LLC | $591.65 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $348.47 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $303.91 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $232.45 | 2019-2021 | |
| Abbott Laboratories | $231.00 | 2021-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $173.73 | 2021-2025 | Nexletol |
| Lilly USA, LLC | $153.19 | 2021-2023 | Jardiance, Mounjaro |
| Pfizer INC. | $143.67 | 2019-2024 | |
| Amarin Pharma, INC. | $109.02 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $58.58 | 2021 | |
| Global Blood Therapeutics, INC. | $57.13 | 2021-2022 | |
| Glaxosmithkline, LLC. | $43.28 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Amgen INC. | $40.73 | 2020-2023 | Repatha, Otezla |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $38.68 | 2023-2024 | Nuzyra |
| Scilex Pharmaceuticals INC. | $37.31 | 2021 | |
| Arbor Pharmaceuticals, INC. | $35.90 | 2019-2021 | |
| Corcept Therapeutics | $24.12 | 2023 | Korlym |
| Dexcom, INC. | $24.08 | 2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $22.31 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.13 | 2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $19.38 | 2021 | |
| Merck Sharp & Dohme LLC | $19.12 | 2019 | |
| Phadia US INC. | $17.34 | 2023 | Immunocap |
| Avanir Pharmaceuticals, INC. | $16.90 | 2019 | |
| Medicure Pharma INC. | $13.64 | 2025 | Zypitamag |
| Sanofi Pasteur INC. | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Fraser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.